Healthcare -
Drug Manufacturers - General - NASDAQ - FR
$ 56.72
4.13 %
$ 142 B
Market Cap
24.66
P/E
1. INTRINSIC VALUE
Balance Sheet
Sanofi
| Current Assets | 42.6 B |
| Cash & Short-Term Investments | 7.93 B |
| Receivables | 10.6 B |
| Other Current Assets | 24 B |
| Non-Current Assets | 90.2 B |
| Long-Term Investments | 3.26 B |
| PP&E | 11.6 B |
| Other Non-Current Assets | 75.4 B |
| Current Liabilities | 29.2 B |
| Accounts Payable | 7.55 B |
| Short-Term Debt | 4.47 B |
| Other Current Liabilities | 17.1 B |
| Non-Current Liabilities | 25.8 B |
| Long-Term Debt | 13.4 B |
| Other Non-Current Liabilities | 12.3 B |
EFFICIENCY
Earnings Waterfall
Sanofi
| Revenue | 44.3 B |
| Cost Of Revenue | 13.2 B |
| Gross Profit | 31.1 B |
| Operating Expenses | 23.8 B |
| Operating Income | 7.25 B |
| Other Expenses | 1.76 B |
| Net Income | 5.5 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sanofi
| Net Income | 5.5 B |
| Depreciation & Amortization | 3.59 B |
| Capital Expenditures | -3.2 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -615 M |
| Others | 517 M |
| Free Cash Flow | 5.89 B |
Wall Street Analysts Price Targets
Sanofi
Wall Street analysts predict an average 1-year price target for SNY of $59.7 , with forecasts ranging from
a
low of
$55 to a high of $64 .
SNY Lowest Price Target
Wall Street Target
55 USD
-3.03%
SNY Average Price Target
Wall Street Target
59.7 USD
5.20%
SNY Highest Price Target
Wall Street Target
64 USD
12.83%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
2.2 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Sanofi
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi in its ability to dramatically boost the productivity of researchers. Sanofi's strong financials provide a solid base to fuel AI-driven growth.
seekingalpha.com
- 1 week ago
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R.
globenewswire.com
- 1 week ago
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
zacks.com
- 1 week ago
Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
seekingalpha.com
- 2 weeks ago
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
globenewswire.com
- 2 weeks ago
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.
globenewswire.com
- 2 weeks ago
Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
reuters.com
- 3 weeks ago
Press Release: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation.
globenewswire.com
- 3 weeks ago
MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI
MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to FLISINT®, an infectious disease DMTI, from SANOFI WINTHROP INDUSTRIE (Gentilly - France). FLISINT® (fumagillin) is recognised as the only treatment capable of overcoming Enterocytozoon bieneusi microsporidia infections. This opportunistic germ develops in clinical situations of immunosuppression (e.
businesswire.com
- 3 weeks ago
L'Oréal to raise €3bn by selling block of shares back to Sanofi
L'Oréal will raise €3 billion by selling 29.6 million Sanofi shares back to Sanofi to cut its stake in the drugmaker. The French cosmetics giant, which also owns Garnier and Lancome, sold the shares back to Sanofi for €101.5 apiece as part of an effort to "optimize" its balance sheet after a recent acquisition spree.
proactiveinvestors.co.uk
- 4 weeks ago
Agreement Between L'Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L'Oréal
AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASE BY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL
globenewswire.com
- 4 weeks ago
Press Release: Sanofi announces buy back of shares from L'Oréal
Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.
globenewswire.com
- 4 weeks ago
8. Profile
Summary
Sanofi SNY
COUNTRY
FR
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 142 B
Dividend Yield
0.00%
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact
54, Rue La BoEtie, Paris, 75008
https://www.sanofi.com
IPO
Date
July 1, 2002
Employees
82878
Officers
Mr. Roy Papatheodorou
Executive Vice President & General Counsel
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Mr. Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Dante Beccaria
Global Compliance Officer & Vice President
Mr. Josep Catlla
Head of Communications
Mr. François-Xavier Roger
Executive Vice President & Chief Financial Officer
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Thomas Kudsk Larsen
Head of Investor Relations
Ms. Madeleine Roach
Executive Vice President & Head of Business Operations
Mr. Paul Hudson
Chief Executive Officer & Director